We report a 41-year-old woman who developed histology-and colonoscopy-proven ischemic colitis with the use of naratriptan not exceeding the maximum 2 doses a day and 3 days per week and without a known medical or cardiovascular history. By exclusion of other causes of colonic ischemia, naratriptan was considered the sole causal agent. Discontinuation of naratriptan resulted in a complete clinical recovery. To date, our patient is the youngest known patient to develop ischemic colitis on isolated naratriptan in the setting of no known medical risk factors or predisposing medical condition. Even though triptans are commonly used for the abortive treatment of migraine headaches, such a reported side effect is rare; however, careful assessment and individual patient-based treatment is advised. I schemic colitis, the most common form of intestinal ischemia, has been associated with advanced age, cardiovascular disease, drug therapy, and vascular surgery ( 1 ) . It manifests as a spectrum of injury, from transient self-limited ischemia involving the mucosa and submucosa to acute fulminant ischemia with transmural infarction that may progress to necrosis and death. Although there are several causes, the most common mechanism is an acute, self-limited compromise in intestinal blood fl ow ( 2 ) . We report a case of ischemic colitis due to a triptan, whose therapeutic eff ect is based on vasoconstriction of the cerebral circulation, which leads to cranial vessel constriction, inhibition of neuropeptide release, and reduced transmission in trigeminal pathways ( 3, 4 ) .
CASE REPORT
A 41-year-old woman with a longstanding history of chronic migraines without aura presented to the emergency department with severe lower abdominal cramping pain with frequent episodes (12-20 episodes in 8-10 hours) of bloody diarrhea accompanied by nausea without vomiting. Th e patient's headache history dated back to the age of 20 years. At that time, her headaches were less frequent and severe. At age 30, she sought medical attention from a neurologist and had preventive medications prescribed. At the time of presentation, she had been using naratriptan 2.5 mg for acute migraines for 2 years-no more than 3 days a week and not more than 2 doses a day; she did not combine naratriptan with any analgesic. Her last dose was about 12 hours prior to presentation. Other medications included desvenlafaxine, bupropion, lamotrigine, and clonazepam. Previous brain magnetic resonance imaging without contrast and a magnetic resonance angiogram with contrast were normal. She had tried topiramate, nadolol, and divalproex sodium in the past, with no response in headache frequency and severity.
Th e patient had not taken any oral contraceptive pills for over 4 years. She denied physical exercise, use of illicit drugs, and smoking; had no recent history of sick contacts, travel outside the United States, or antibiotic exposure; and denied the ingestion of shellfi sh or undercooked food. In addition, she had no history of hypertension, diabetes mellitus, or coronary artery disease and no evidence of an autoimmune or hypercoagulable state. Her laboratory fi ndings were normal, as were cultures of urine, blood, and stool and hypercoagulability workup.
Computed tomography (CT) of the abdomen and pelvis with contrast showed colitis from the transverse colon to sigmoid colon. Th e patient was hydrated and a partial colonoscopy on the day following admission revealed patchy areas of moderate to severe congested, erythematous, and ulcerated mucosa in the left colon, extending from 20 to 35 cm consistent with ischemic colitis (Figure 1) . A biopsy showed accumulation of fi brin in the interstitial exudate, with a pink smudgy character of the lamina propria, indicative of loss of tissue and ischemic damage (Figure 2) . Th e patient was treated with intravenous levofl oxacin and metronidazole, bowel rest, and intravenous hydration. She responded well, with resolution of the bloody stool and abdominal pain, and was discharged on the fi fth hospital day. One month and 6 months later, repeat CT scans of the abdomen were normal, and her gastrointestinal symptoms had not recurred. She was followed at a multidisciplinary headache center, and her headache frequency and severity have improved with onabotulinum toxin A injections of 155 units every 3 months.
DISCUSSION
Th is case report demonstrates the occurrence of histologyproven ischemic colitis in the youngest patient to date on a triptan in the absence of major vascular obstruction, atrial fibrillation, blood dyscrasia, other medication use, or an intermittent low-fl ow state of the systemic circulation. We believe the segmental, self-limited colitis observed in this 41-year-old otherwise healthy patient was ischemic in nature. Th is hypothesis is supported by the onset and rapid spontaneous resolution of symptoms, as well as the characteristic distribution of colonic injury. She did not have any other known risk factors that would predispose to ischemic colitis and did not take prescription or illicit drugs commonly associated with gastrointestinal ischemia, such as conjugated estrogens, ergotamine derivatives, and other vasoconstrictive agents. It is therefore likely that the ischemic colitis is due to the naratriptan, even though the dose was within prescribed limit of no more than 2 doses a day and 3 days a week.
Naratriptan's mode of action is through selective agonism of serotonin (5HT1B and 5HT1D receptors) in the cranial arteries; it causes vasoconstriction and reduces sterile infl ammation associated with antidromic neuronal transmission correlating with relief of migraine. Th e onset of action is 1 to 2 hours; time to peak, 2 to 3 hours; and half-life, 6 hours. When prescribed to patients with a low risk of cardiovascular events, triptans have been proven to be safe without evidence of increased occurrence of ischemic conditions ( 3, 4 ) . Th e frequency of ischemic colitis associated with naratriptan, according to the Netherlands Pharmacovigilance Centre, is rare (<1:1000). Th ere have been four case reports to date of naratriptan-associated ischemic colitis. One involved naratriptan in conjunction with an oral contraceptive pill, which may have increased the risk of developing ischemia (4) (5) (6) . Th e other cases reported patients older than 50 years (3) (4) (5) (6) (7) (8) . In addition, there have been reports of sumatriptan-associated ischemic colitis and naratriptan-associated ischemic colitis with concurrent use of oral contraceptives or other medications including quetiapine and topiramate ( 7, 8 ) . While triptans have proven effi cacious in relieving the pain of acute migraine headaches, predisposition to ischemic events, either on the basis of underlying vascular disease or concomitant drug/medication use, should be assessed in all patients in whom triptan therapy is being considered. Hematoxylin and eosin-stained biopsy section of (a) control and (b) case. In the control, the stroma is pale due to the predominance of watery interstitial fluid, the capillaries are readily seen, the glands are not shrunken ("withered"), the surface epithelium is intact, and the epithelial cells of the glands and surface are tall, regular, and have well preserved nuclei and cytoplasm. The biopsy from the case shows degeneration of the surface epithelium, "withered glands," and eosinophilic, smudgy lamina propria. a b
